Company Nymox Pharmaceutical Corporation Nasdaq
Equities
CA67076P1027
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Paul Averback
CEO | Chief Executive Officer | 73 | 30/95/30 |
Patrick Doody
BRD | Director/Board Member | - | 12/23/12 |
Director/Board Member | - | 21/23/21 | |
Suresh Kalbag
PRN | Corporate Officer/Principal | - | - |
General Counsel | - | 06/20/06 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
David S. Morse
BRD | Director/Board Member | 67 | 08/06/08 |
Paul Averback
CEO | Chief Executive Officer | 73 | 30/95/30 |
Director/Board Member | 88 | 01/15/01 | |
Director/Board Member | - | 21/23/21 | |
Patrick Doody
BRD | Director/Board Member | - | 12/23/12 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 93,265,000 | 54,049,529 ( 57.95 %) | 0 | 57.95 % |
Company contact information
Sector
Sales per region
1st Jan change | Capi. | |
---|---|---|
+21.72% | 46.93B | |
+37.63% | 39.08B | |
-8.35% | 38.48B | |
+29.09% | 31.01B | |
-13.75% | 26.14B | |
+11.28% | 25.88B | |
+35.84% | 12.53B | |
-6.69% | 11.36B | |
-12.37% | 10.65B |
- Stock Market
- Equities
- NYMXF Stock
- Stock
- Company Nymox Pharmaceutical Corporation